STOCK TITAN

Adicet Bio, Inc. - $ACET STOCK NEWS

Welcome to our dedicated page for Adicet Bio news (Ticker: $ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adicet Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adicet Bio's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.99%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.99%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
management
Adicet Bio, Inc.

Nasdaq:ACET

ACET Rankings

ACET Stock Data

119.15M
49.05M
1.42%
67.94%
9.36%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
BOSTON

About ACET

adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicet’s gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v